Copyright © 2003 by the European Society of Cardiology.
Clinical research
Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina
a Royal Brompton and Harefield NHS Trust, London, UK
b University of Oklahoma Health Sciences Center and VA Medical Center, Oklahoma City, OK, USA
c Heart Health Institute, Calgary, Canada
d Syracuse Preventive Cardiology, Syracuse, NY, USA
e Pfizer Global Research and Development, Sandwich, UK
f Pfizer Global Research and Development, New London, CT, USA
g Hungarian Institute of Cardiology, Budapest, Hungary
* Corresponding author: Kim M. Fox, MD, Royal Brompton and Harefield Trust, Sydney Street, London, SW3 6NP, UK. Tel.: +44-20-7351-8626; fax: +44-20-7351-8629
E-mail address: k.fox{at}rbh.nthames.nhs.uk
Received 27 March 2003; revised 11 September 2003; accepted 19 September 2003
Abstract
Aims The aim of this study was to evaluate whether sildenafil, used for treatment of erectile dysfunction (ED), affects the exercise tolerance and ischaemic threshold in men with exercise-induced angina not taking nitrates.
Methods This was a double-blind placebo-controlled study in men with ED and chronic stable angina, assessing the effect of sildenafil on time to limiting angina during incremental treadmill exercise. Patients remained on their antianginal therapy and received a 100-mg dose of sildenafil or placebo 1h prior to treadmill exercise. Other measurements included times to onset of angina, 1-mm ST-segment depression, and total exercise time.
Results Adjusted treatment differences for the time to limiting angina, time to onset of angina, total exercise time, and time to 1-mm ST-segment depression were (mean±SE) 20±10s (95% CI, 1–39; P=0.040), 32±11s (95% CI, 11–53; P=0.004), 20±10s (95% CI, 0–39; P=0.049), and 12±17s (95% CI, –21 to 45, P=0.48), respectively, in favour of sildenafil. There were no serious treatment-related adverse events.
Conclusion Sildenafil was well tolerated and did not adversely affect any exercise parameter in men with coronary artery disease and ED. Favourable trends in total exercise duration and times to onset of angina and limiting angina were recorded with sildenafil use.
Key Words: Angina • Erectile dysfunction • Exercise tolerance • Ischaemia • Sildenafil citrate • ST-segment depression
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Reffelmann and R. A. Kloner Phosphodiesterase 5 inhibitors: are they cardioprotective? Cardiovasc Res, July 15, 2009; 83(2): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. M. Cheng and S. R. Berhane Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors American Journal of Lifestyle Medicine, May 1, 2009; 3(3): 201 - 211. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Crea, P. G. Camici, R. De Caterina, and G. A. Lanza CHAPTER 17 Chronic Ischaemic Heart Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jackson CHAPTER 15c Erectile Dysfunction ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. M. Luks and E. R. Swenson Medication and Dosage Considerations in the Prophylaxis and Treatment of High-Altitude Illness Chest, March 1, 2008; 133(3): 744 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, K. Fox, M. A. A. Garcia, D. Ardissino, P. Buszman, P. G. Camici, F. Crea, C. Daly, G. De Backer, P. Hjemdahl, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology Eur. Heart J., June 1, 2006; 27(11): 1341 - 1381. [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Thethi, N. O. Asafu-Adjaye, and V. A. Fonseca Erectile Dysfunction Clin. Diabetes, July 1, 2005; 23(3): 105 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Gori, S. Sicuro, S. Dragoni, G. Donati, S. Forconi, and J. D. Parker Sildenafil Prevents Endothelial Dysfunction Induced by Ischemia and Reperfusion via Opening of Adenosine Triphosphate-Sensitive Potassium Channels: A Human In Vivo Study Circulation, February 15, 2005; 111(6): 742 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Kloner Cardiovascular Effects of the 3 Phosphodiesterase-5 Inhibitors Approved for the Treatment of Erectile Dysfunction Circulation, November 9, 2004; 110(19): 3149 - 3155. [Full Text] [PDF]
|
|